76 related articles for article (PubMed ID: 3066300)
21. Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages.
Fidler IJ; Raz A; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1980 Dec; 40(12):4460-6. PubMed ID: 7002293
[TBL] [Abstract][Full Text] [Related]
22. [Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice and rats].
Ogura T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):689-96. PubMed ID: 3083782
[TBL] [Abstract][Full Text] [Related]
23. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes.
Fidler IJ; Fogler WE; Kleinerman ES; Saiki I
J Immunol; 1985 Dec; 135(6):4289-96. PubMed ID: 3934281
[TBL] [Abstract][Full Text] [Related]
24. Macrophage activation: synergism between hybridoma MAF and poly(I). Poly(C) delivered by liposomes.
Pidgeon C; Schreiber RD; Schultz RM
J Immunol; 1983 Jul; 131(1):311-4. PubMed ID: 6408176
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic effects of alkylphosphocholines or alkylphosphocholine-liposomes and macrophages on tumor cells.
Zeisig R; Jungmann S; Fichtner I; Daemen T; Arndt D
Anticancer Res; 1994; 14(5A):1785-9. PubMed ID: 7847811
[TBL] [Abstract][Full Text] [Related]
26. Human alveolar macrophages: potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide.
Sone S; Tsubura E
J Immunol; 1982 Sep; 129(3):1313-7. PubMed ID: 7108208
[TBL] [Abstract][Full Text] [Related]
27. Evidence for macrophage involvement in the enhancement of tumor growth delay with X-ray/Fluosol-DAR/O2 combination therapy.
Holden SA; Teicher BA; McIntosh NL; Rose CM
Anticancer Res; 1987; 7(3 Pt B):385-90. PubMed ID: 3115174
[TBL] [Abstract][Full Text] [Related]
28. Gender dimorphism of macrophage response to GMCSF and IL-4 for differentiation into dendritic cells.
Gupta V; Singh SM
Am J Reprod Immunol; 2008 Jul; 60(1):43-54. PubMed ID: 18593437
[TBL] [Abstract][Full Text] [Related]
29. Preparation and antitumor effect of macrophage activating factor (MAF) encapsulated in liposomes bearing a monoclonal anti-human melanoma (A375) antibody.
Watanabe Y; Uchida E; Higuchi M; Imai Y; Osawa T
J Biol Response Mod; 1987 Oct; 6(5):556-68. PubMed ID: 3316511
[TBL] [Abstract][Full Text] [Related]
30. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines.
Sone S; Poste G; Fidler IJ
J Immunol; 1980 May; 124(5):2197-202. PubMed ID: 7365253
[TBL] [Abstract][Full Text] [Related]
31. B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens.
Crawford RM; Finbloom DS; Ohara J; Paul WE; Meltzer MS
J Immunol; 1987 Jul; 139(1):135-41. PubMed ID: 3108395
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy of a murine lymphoma by adoptive transfer of syngeneic macrophages activated with bisantrene.
Wang BS; Lumanglas AL; Durr FE
Cancer Res; 1986 Feb; 46(2):503-6. PubMed ID: 3940628
[TBL] [Abstract][Full Text] [Related]
33. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats.
Kawase I; Komuta K; Namba M; Yokota S; Ogura T; Kishimoto S
Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators.
Hudson MM; Snyder JS; Jaffe N; Kleinerman ES
Cancer Res; 1988 Sep; 48(18):5256-63. PubMed ID: 3261632
[TBL] [Abstract][Full Text] [Related]
35. Maleic vinyl ether activation of murine macrophages against lung-metastasizing tumors.
Loveless SE; Munson AE
Cancer Res; 1981 Oct; 41(10):3901-6. PubMed ID: 7285000
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of murine sarcoma by adoptive transfer of resident peritoneal macrophages proliferating in culture.
Bartholeyns J; Lombard Y; Poindron P
Anticancer Res; 1988; 8(1):145-51. PubMed ID: 3358630
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of lymphokine-induced macrophage microbicidal activity against Leishmania major by liposomes: characterization of the physicochemical requirements for liposome inhibition.
Gilbreath MJ; Hoover DL; Alving CR; Swartz GM; Meltzer MS
J Immunol; 1986 Sep; 137(5):1681-7. PubMed ID: 3745916
[TBL] [Abstract][Full Text] [Related]
38. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ
Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073
[TBL] [Abstract][Full Text] [Related]
39. Suppression of natural tumor resistance by tumor promoters.
Keller R; Keist R; Köppel P; Hecker E
Carcinog Compr Surv; 1982; 7():643-5. PubMed ID: 7039836
[TBL] [Abstract][Full Text] [Related]
40. Binding of calmodulin to the microfilament network correlates with induction of a macrophage tumoricidal response.
Mecham JO; Soong MM; Cain CA; Koehm S; Goff J; Tompkins WA
J Immunol; 1985 May; 134(5):3516-23. PubMed ID: 3884713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
